Form 4: Plus Therapeutics CEO Marc Hedrick Acquires Stock Options
SEC Form 4 Filing
Plus Therapeutics CEO Marc Hedrick was granted stock options to purchase 197,595 shares of common stock.
Summary
- On September 11, 2024, Marc H. Hedrick, CEO of Plus Therapeutics, Inc., was granted stock options to purchase 197,595 shares of the company's common stock.
- The exercise price of these options is $1.26 per share.
- The options vest in equal monthly installments over four years, beginning on the issuance date, and fully vest upon a change of control event.
- The options expire on September 11, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests. The sentiment is moderately positive as it indicates continued commitment from the CEO.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment from the CEO.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
- The vesting schedule of four years with monthly installments is a typical arrangement to ensure continued service and commitment from the executive.
- Change of control vesting is also a common provision to protect the executive in the event of a merger or acquisition.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of the transaction: Grant of stock options to Marc H. Hedrick. |
| 09/11/2034 | Expiration date of the stock options. |
Keywords
stock options, Form 4, CEO, Marc Hedrick, Plus Therapeutics, PSTV, executive compensation, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.